TP53 and familial pancreatic carcinoma: In another study, scholars found that inhibiting STAT3 in pancreatic cancer cells reduces the expression level of mutant-P53 through embaring HSP90 and molecules related to the mevalonate pathway, and the expression of mutant-P53 mediates the phosphorylation of STAT3 in turn (26).